Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy

Cancer Genetics and Cytogenetics
Torrey M ParkerDonna L Johnston

Abstract

Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder that often results in progression to acute myeloid leukemia (AML), particularly when additional genetic abnormalities are present, such as monosomy 7. Treatment options for this condition are limited. Spontaneous remission has occurred in a small number of cases. In the present case, a previously healthy 3-year-old boy diagnosed with MDS and monosomy 7 achieved spontaneous remission without intervention 30 months after initial diagnosis. Such findings highlight the need to monitor patients closely for evidence of spontaneous remission.

References

Feb 1, 1990·Cancer Genetics and Cytogenetics·D DaghistaniR Curless
Feb 26, 1987·The New England Journal of Medicine·J KereA de la Chapelle
Sep 10, 2003·Pediatric Hematology and Oncology·Elaine W LeungYigal Dror

❮ Previous
Next ❯

Citations

Dec 14, 2011·Hematology·Charlotte M Niemeyer, Irith Baumann
May 11, 2011·British Journal of Haematology·Henrik Hasle, Charlotte M Niemeyer
Dec 9, 2008·Cancer Genetics and Cytogenetics·Eliane Ferreira RodriguesTeresa de Souza Fernandez
May 10, 2018·Journal of Pediatric Hematology/oncology·Holly J Edington, Eric J Lowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.